Psychedelic News and Analysis Made Simple for Investors
Psychedelic Invest is a resource for those looking to invest in the burgeoning psychedelic industry.
Track the entire psychedelic market
We’ve developed the first all encompassing index to track the public psychedelic marketplace.
Explore the Index
Just Some of the Data we Cover
Latest News
Press
Jul 26
•
4 min read
NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) — Psyence Group Inc (“Psyence Group“) (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is pleased to announce that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) (“PBM” or “Psyence Biomed“), has announced the export of nature-derived psilocybin to…
Press
SARASOTA, FL, July 26, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that CEO Eric Weisblum will present at the H.C. Wainwright 25th Annual Global Investment Conference to be…
Jul 26
•
3 min read
Press
Toronto, Ontario–(Newsfile Corp. – July 25, 2024) – Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) (“Braxia Scientific”, or the “Company”), today announced further to its press release of July 15, 2024, that the Ontario Securities Commission (the “OSC”) has denied the Company’s application for a voluntary management cease trade order (the “MCTO”)…
Jul 26
•
3 min read
Health & Science
Psilocybin, a key compound in several species of hallucinogenic mushrooms, is at the forefront of the psychedelic renaissance. It has shown promise in treating various conditions such as anxiety, addiction, and depression. When ingested, psilocybin converts into psilocin, interacting with serotonin receptors in the brain. This interaction alters consciousness and can lead to significant mood…
Jul 25
•
5 min read
Press
Psyence Biomedical Ltd. announced the export of nature-derived psilocybin to Australia and provided an update on its upcoming Phase IIb clinical trial evaluating nature-derived psilocybin as a potential treatment for Adjustment Disorder following an advanced cancer diagnosis in the Palliative Care context. The Company previously announced that it had entered into partnerships with Fluence, a…
Jul 25
•
2 min read
Press
Enveric Biosciences (NASDAQ: ENVB) (“Enveric”), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, today announced encouraging EB-003 preclinical results indicating the potential for the drug candidate to be delivered via oral administration with significant brain exposure in rodent models at potential therapeutic doses. EB-003 is a novel, neuroplastogenic…
Jul 25
•
3 min read
Press
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced the export of nature-derived psilocybin to Australia and provided an update on its upcoming Phase IIb clinical trial evaluating nature-derived psilocybin as a potential treatment for Adjustment Disorder following an advanced cancer diagnosis in the Palliative Care context. The Company previously…
Jul 24
•
4 min read
Explore the Psychedelic Landscape
Learn more about the psychedelic companies changing the industry.